Back to Clinical Trials Overview

Your search for "Lung" returned 16 results:

An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (ESBRIETĀ®) in Combination with Nintedanib (OFEVĀ®) in Patients with Idiopathic Pulmonary Fibrosis
Principal Investigator(s): Sakshi Dua

A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma
Principal Investigator(s): Linda Rogers

A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment
Principal Investigator(s): Louis DePalo

A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease
Principal Investigator(s): Neil Schachter

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Principal Investigator(s): E. Neil Schachter

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)
Principal Investigator(s): Maria Padilla

WTC CHEST (Pulmonary Abnormalities, Diastolic Dysfunction, and World Trade Center Exposure: Implications for Diagnosis and Treatment)
Principal Investigator(s): Mary Ann McLaughlin, MD MPH

American Legacy Smoking Cessation Study
Principal Investigator(s): Claudia I. Henschke

Determinants fo Undertreatment Amoung Patients with Chronic Obstructive Pulmonary Disease
Principal Investigator(s): Wisnivesky, Juan P

A Phase II Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis
Principal Investigator(s): Maria Padilla

Pulmonary Diseases from Secondhand Smoke
Principal Investigator(s): Claudia I. Henschke

A Phase 2 Open-label Dose-Escalation Study to Evaluate the Safety Tolerability and Efficacy of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis [Protocol Number FGCL-3019-049]
Principal Investigator(s): Maria Padilla

Clinic-based vs. home-based support to improve outcomes for older asthmatics
Principal Investigator(s): Alex Federman

Study MEA117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients
Principal Investigator(s): Gwen Skloot

Asthma Mobile Health App study
Principal Investigator(s): Yvonne Chan

A Multi-Centre Open-Label Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
Principal Investigator(s): Gwen Skloot